Vaginal ring delivery of hormone replacement therapy - A review

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 2, 2003, Pages 201-212

  Dezarnaulds, Gabrielle ^b   Fraser, Ian S ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Hormone delivery system; Hormone replacement therapy; Menopausal vaginal ring; Oestrogen; Progestogen

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; LEVONORGESTREL; PLACEBO; PROGESTERONE; STEROID;

BLEEDING; BREAST TENDERNESS; CLINICAL STUDY; CREAM; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HEADACHE; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; NAUSEA; POSTMENOPAUSE; RETROSPECTIVE STUDY; REVIEW; UROGENITAL SYSTEM; VAGINA ATROPHY; VAGINA DISCHARGE; VAGINA PESSARY; VAGINA RING;

EID: 0344643413     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.2.201     Document Type: Review

References (46)

1. SPEROFF L, GLASS RH, KASE NG: Clinical Gynecological Endocrinology and Infertility Lippincot Williams & Wilkins, Maryland, MD, USA (1999).
2. NOTELOVITZ M: Urogenital atrophy and low-dose vaginal estrogen therapy. Menopause (2000) 7:140-142.
3. BACHMANN GA, NEVADUNSKY NS: Diagnosis and treatment of atrophic vaginitis. Am. Fam. Physician. (2000) 61:3090-3096.
4. MANSON JE, MARTIN KA: Postmenopausal hormone-replacement therapy. N. Engl. J. Med. (2001) 345:34-40.
5. HAAS S, WALSH B, EVANS S, KRACHE M, RAVNIKAR V, SCHIFF I: The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period. Obstet. Gynecol. (1988) 71:671-676.
6. NASH HA, BRACHE V, ALVAREZ-SANCHEZ F, JACKANICZ TM, HARMON TM: Estradiol delivery by vaginal rings: potential for hormone replacement therapy. Maturitas (1997) 26:27-33.
7. FELSON DT, ZHANG Y, HANNAN MT, KIEL DP, WILSON PWF, ANDERSON JJ: The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med. (1993) 329:1141-1146.
8. DELMAS PD: Osteoporosis IV: treatment of postmenopausal osteoporosis. Lancet (2002) 359:2018-2026.
9. TORGERSON DJ, BELL-SYER SE: Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomized trials. BMC Musculoskelet. Disord. (2001) 2:7. Also available online at: http://www.biomedcentral.com/ 1471-2474/2/7
10. TORGERSON DJ, BELL-SYER SEM: Hormone replacement therapy and prevention of nonvertebral fractures. A meta-analysis of randomized trials. JAMA (2001) 285:2891-2897.
11. CARDOZO L, BACHMANN G, MCGLISH D, FONDA D, BIRGERSON L: Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet. Gynecol. (1998) 92:722-727.
12. SMITH RJN, STUDD JWW: Recent advances in hormone replacement therapy. Br. J. Hosp. Med. (1993) 49:799-809.
13. GRADY D, GEBRETSADIK T, KERLIKOWSKE K, ERNSTER V, PETITTI D: Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol. (1995) 85:304-313.
14. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA (1995) 273:199-208.
15. MACHT DI: The absorption of drugs and poisons through the vagina. J. Pharmacol. Path. (1918) 10:509-510.
16. DZUIK P, COOK B: Passage of steroids through silicone rubber. Endocrinology (1966) 78:208-211.
17. PSCHERA H, HJERPE A, CARLSTRÖM K: Influence of the maturity of the vaginal epithelium upon the absorption of vaginally administered estradiol-17β and progesterone in postmenopausal women. Gynecol. Obstet. Invest. (1989) 27:204-207.
18. FRASER IS, YUAN W: Vaginal rings as delivery systems for contraception and hormone replacement therapy. In: Contributions to Obstetrics and Gynaecology (Vol. 4). Arulkumaran S, Ng SC (Eds), Oxford University Press, Oxford, UK (1996):259-270.
19. LANDGREN B-M, AEDO A-R, JOHANNISSON E, CEKAN SK: Pharmacokinetic and pharmacodynamic effects of vaginal rings releasing levonorgestrel at a rate of 27 μg/24 hours: A pilot study. Contracept. (1994) 49:139-150.
20. BALLAGH S: Vaginal ring hormone delivery systems in contraception and menopause. Clin. Obstet. Gynecol. (2001) 44:106-113.
21. TIMMER CJ, APTER D, VOORTMAN G: Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. Contracept. (1990) 42:629-642.
22. SCHMIDT G, ANDERSSON S, NORDLE Ö, JOHANSSON C, GUNNARSSON P: Release of 17β-oestradiol from a vaginal ring in postmenopausal women: pharmacokinetic evaluation. Gynecol. Obstet. Invest. (1994) 38:253-260.
23. HOLMGREN P, LINDSKOG M, VON SCHOULTZ B: Vaginal rings for continuous low-dose release of oestradiol in the treatment of urogenital atrophy. Maturitas (1989) 11:55-63.
24. SMITH P, HEIMER G, LINDSKOG M, ULMSTEN U: Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas (1993) 16:145-154.
25. GABRIELSSON J, WALLENBECK I, BIRGERSON L: Pharmacokinetic data on estradiol in light of the estring concept. Estradiol and estring pharmacokinetics. Acta Obstet. Gynecol. Scand. Suppl. (1996) 163:26-31.
26. NAESSEN T, RODRIGUEZ-MACIAS K, LITHELL H: Serum lipid profile improved by ultra-low dose of 17β-estradiol in elderly women. J. Clin. Endocrinol. Metab. (2001) 86:2757-2762.
27. NASH HA, ALVAREZ-SANCHEZF, MISHELL DR Jr, FRASER IS, MARUO T, HARMON TM: Estradiol-delivering vaginal rings for hormone replacement therapy. Am. J. Obstet. Gynecol. (1999) 181:1400-1406.
28. MARUO T, MISHELL D, BEN-CHETRIT A, HOCHNER-CELNIKIER D, HAMADA AL, NASH H:Vaginal rings delivering progesterone and estradiol for hormone replacement therapy. Fertil. Steril. (In Press).
29. FACHIN R, DE ZIEGLER D, BERGERON C, RIGHINI C, TORRISI C, FRYDMAN R: Transvaginal administration of progesterone. Obstet. Gynecol. (1997) 90:396-401.
30. MILES R, PAULSON R, LOBO R, PRESS M, DAHMOUSH L, SAUER M: Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil. Steril. (1994) 62:485-490.
31. HENRIKSSON L, STJERNQUIST M, BOQUIST L, CEDERGREN I, SELINUS I: A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am. J. Obstet. Gynecol. (1996) 174:85-92.
32. ERIKSEN BC: A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am. J. Obstet. Gynecol. (1999) 180:1072-1079.
33. HENRIKSSON L, STJERNQUIST M, BOQUIST L, ÅLANDER U, SELINUS I: A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs or urogenital atrophy. Am. J. Obstet. Gynecol. (1994) 171:624-632.
34. AYTON RA, DARLING GM, MURKIES AL et al.: A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br. J. Obstet. Gynaecol. (1996) 103:351-358.
35. BARENTSEN R, VAN DE WEIJER PHM, SCHRAM JHN: Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur. J. Obstet. Gynecol. Reprod. Biol. (1997) 71:73-80.
36. LOSE G, ENGLEV E: Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. Br. J. Obstet. Gynaecol. (2000) 107:1029-1034.
37. CASPER F, PETRI E: Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. Int. Urogynecol. J. Pelvic Floor Dysfunct. (1999) 10(3):171-176.
38. BOMAN K: Influence of oestrogen on growth of endometrial carcinoma. Anti-cancer Res. (1990) 10:173-176.
39. NAESSEN T, RODRIGUEZ-MACIAS K: Endometrial thickness and uterine diameter not affected by ultralow doses of 17β-estradiol in elderly women. Am. J. Obstet. Gynecol. (2002) 186:944-947.
40. NAESSEN T, BERGLUND L, ULMSTEN U: Bone less in elderly women prevented by ultralow doses of parenteral 17β-estradiol. Am. J. Obstet. Gynecol. (1997) 177:115-119.
41. WALSH BW, SCHIFF I, ROSNER B, GREENBERG L, RAVNIKAR B, SACKS FM: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Engl. J. Med. (1991) 325:1196-1204.
42. LOBO RA: Clinical review 27: effects of hormone replacement on lipids and lipoproteins in postmenopausal women. J. Clin. Endocrinol. Metab. (1991) 73:925-930.
43. FAUNDES A, HARDY E, REYES Q, PASTENE L, PORTES-CARASCO R: Acceptability of the contraceptive vaginal ring by rural and urban populations in two Latin American countries. Contracept. (1981) 24:393-414.
44. ELDER M, LAWSON J, ELSTEIN M, NUTTALL I: The efficacy and acceptability of a low-dose levonorgestrel intravaginal ring for contraception in a UK cohort. Contracept. (1991) 43:129-137.
45. WEISBERG E, FRASER I, MISHELL D, LACARRA M, BARDIN C: The acceptability of a combined oestrogen-progestogen contraceptive vaginal ring. Contracept. (1995) 51:39-44.
46. NORMAN T, MORSE C, DENNERSTEIN L: Comparative bioavailability of orally and vaginally administered progesterone. Fertil. Steril. (1991) 56:1034-1039.